2015 U.S.-Booked Air Volume: $90 million
Principal Air
Suppliers: American, Delta,
United
Principal Online
Booking Tool: Concur Travel
Principal
Expense Supplier: Concur Expense
Consolidated
U.S. TMC: BCD Travel
Previously
known as Actavis, global specialty pharmaceutical company Allergan enters the
Corporate Travel 100 for the first time this year with a BTN estimate of $90 million in U.S.-booked air volume,
following a year of massive growth. Net revenue more than doubled from $6.7
billion in 2014 to more than $15 billion in 2015, and the net contribution from
the U.S. brands segment also more than doubled from $4.5 billion in 2014 to
$9.1 billion in 2015. Selling and marketing expenses, which includes travel
costs, more than doubled from $1.2 billion in 2014 to $2.9 billion in 2015.
The
massive growth was the result of six acquisitions that prompted repeated
supplier contract renegotiations. Subsequent transactions in 2016 reduced its
size, but following an aborted effort to merge with Pfizer, the company
continues to make acquisitions. In North America, Allergan has a high level of
adoption for its Concur online booking and expense tool and uses a meetings
tool and internal and third-party planners to manage its substantial meetings
expenses.
The
company, which operated in more than 100 countries in 2015, began its surge
with the Allergan acquisition, which closed on March 17, 2015. The addition of
the legacy Allergan’s therapeutic franchises in ophthalmology, neurosciences
and medical aesthetics/dermatology/plastic surgery complemented the company’s
existing central nervous system, gastroenterology, women’s health and urology
franchises. The combined company benefited from legacy Allergan’s global brand
equity and consumer awareness of key products, including Botox and Restasis.
The transaction also expanded its presence and product reach across international
markets, with strengthened commercial positions across Canada, China, Europe,
India, the Middle East, Latin America and Southeast Asia. Other acquisitions
last year included Auden Mckenzie, Oculeve, Kythera, Northwood Medical
Innovation and AqueSys. As of Dec. 31, 2015, Allergan had 31,200 employees.
Approximately 14,900 of them transferred to Teva in August 2016 when Teva
acquired the company’s global generic pharmaceuticals business and other
assets.